#1 Clinical Trials Search in Europe

Prax-628

PRAX-628 is an investigational drug currently being studied in clinical trials for the treatment of epilepsy. These trials aim to evaluate the safety, efficacy, and pharmacokinetics of PRAX-628 in adults with various forms of epilepsy, including those with focal seizures and light-induced epileptic responses. The ongoing research seeks to determine if PRAX-628 can effectively reduce seizure frequency and improve the quality of life for patients living with epilepsy.

Table of Contents

What is PRAX-628?

PRAX-628 is a new medication being developed to treat epilepsy, a neurological disorder characterized by recurrent seizures[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety in patients with various forms of epilepsy. PRAX-628 is taken orally in the form of a capsule[2].

How Does PRAX-628 Work?

While the exact mechanism of action is not fully disclosed in the available information, PRAX-628 is likely designed to reduce the frequency and severity of seizures in people with epilepsy. Many anti-seizure medications work by altering the electrical activity in the brain or by affecting neurotransmitters (chemical messengers in the brain) to prevent the abnormal firing of neurons that leads to seizures[1].

Current Research on PRAX-628

PRAX-628 is currently being studied in two main clinical trials:

  1. Phase 2 Trial for Photosensitive Epilepsy: This study is evaluating the effect of PRAX-628 on patients with epilepsy who have a specific response to light stimulation, known as a photoparoxysmal electroencephalogram response (PPR)[1]. The main goal is to see if PRAX-628 can reduce or eliminate this response, which could indicate its potential to control seizures.

  2. Phase 2/3 Trial for Focal Seizures: This larger study, called POWER 1, is testing PRAX-628 in adults with focal seizures who are currently taking 1 to 3 anti-seizure medications[2]. The primary aim is to measure how well PRAX-628 reduces the frequency of focal seizures compared to a placebo.

Potential Benefits of PRAX-628

Based on the ongoing research, PRAX-628 may offer several potential benefits for people with epilepsy:

  • Reduction in seizure frequency[2]
  • Possible effectiveness in controlling photosensitive epilepsy[1]
  • An additional treatment option for those who haven’t found success with other medications
  • Potential to improve quality of life for people living with epilepsy

Who Might Benefit from PRAX-628?

PRAX-628 is being studied in two main groups of people with epilepsy:

  1. Adults with photosensitive epilepsy: This includes people who have seizures triggered by flashing lights or certain visual patterns[1].

  2. Adults with focal seizures: These are seizures that start in one area of the brain. The current study includes adults aged 18 to 75 who are already taking 1 to 3 anti-seizure medications but still experiencing seizures[2].

Safety and Side Effects

As PRAX-628 is still in clinical trials, comprehensive information about its safety profile and potential side effects is not yet available. The ongoing studies are carefully monitoring for any adverse events (side effects) and evaluating the overall safety of the medication[1][2].

The researchers are paying close attention to:

  • Changes in vital signs
  • Changes in laboratory test results
  • Changes in heart activity (as measured by ECG)
  • Any signs of suicidal thoughts or behaviors

It’s important to note that all medications can have side effects, and the balance between benefits and risks will be carefully evaluated before PRAX-628 could potentially become available for general use.

Conclusion

PRAX-628 represents a promising new approach in the treatment of epilepsy, particularly for those with photosensitive epilepsy or focal seizures. While the research is still ongoing, the results of these clinical trials could potentially lead to a new treatment option for people living with epilepsy. As always, it’s important for patients to discuss any new treatments with their healthcare providers and to participate in clinical trials only under careful medical supervision.

Aspect Details
Drug Name PRAX-628
Administration Oral capsules
Target Condition Epilepsy (focal seizures and photoparoxysmal responses)
Study Population Adults aged 18-75 with diagnosed epilepsy
Primary Objectives Evaluate efficacy in reducing seizure frequency, assess safety and tolerability
Secondary Objectives Study pharmacokinetics, measure changes in EEG responses, assess quality of life improvements
Key Inclusion Criteria Stable use of 1-3 antiseizure medications, minimum seizure frequency, specific EEG responses
Key Exclusion Criteria Recent epilepsy surgery, progressive neurological diseases, certain psychiatric conditions
Trial Design Randomized, placebo-controlled, single-blind and double-blind studies
Duration Varies by trial, up to 12 weeks of treatment

FAQ

  • What is PRAX-628? PRAX-628 is an experimental drug being tested for the treatment of epilepsy. It is currently undergoing clinical trials to assess its effectiveness and safety in reducing seizures in adults with epilepsy.
  • What types of epilepsy are being studied with PRAX-628? The clinical trials are focusing on adults with focal seizures and those who have a photoparoxysmal response to intermittent photic stimulation (light-induced epileptic response).
  • How is PRAX-628 administered? PRAX-628 is administered orally in the form of capsules. The exact dosage and frequency may vary depending on the specific trial protocol.
  • What are the main goals of the PRAX-628 clinical trials? The main goals are to evaluate the drug's ability to reduce seizure frequency, assess its safety and tolerability, and study its effects on brain activity in people with epilepsy.
  • Who can participate in these clinical trials? Eligibility criteria vary, but generally include adults aged 18-75 with diagnosed epilepsy, specific seizure types, and stable use of current anti-seizure medications. Participants must meet other health criteria and be willing to comply with study requirements.

Ongoing Clinical Trials on Prax-628

  • Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Italy Poland Spain

  • Study on PRAX-628 for Adults with Focal Onset or Generalized Tonic-Clonic Seizures

    Not recruiting

    1 1
    Investigated drugs:
    Germany Spain

  • Study on PRAX-628 for Epilepsy Patients with Light-Induced EEG Response

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on PRAX-628 for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

    Not recruiting

    1 1
    Investigated drugs:
    Italy Poland Spain

Glossary

  • Photoparoxysmal EEG response (PPR): An abnormal brain wave pattern seen on an electroencephalogram (EEG) in response to flashing lights, which is associated with certain types of epilepsy.
  • Focal seizures: Seizures that start in one area of the brain, also known as partial seizures. They can be simple (person remains aware) or complex (awareness is affected).
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect, used as a control in clinical trials.
  • Antiseizure medication (ASM): Drugs used to prevent or reduce the frequency and severity of epileptic seizures.
  • Electroencephalogram (EEG): A test that records electrical activity in the brain, often used to diagnose and monitor epilepsy.
  • Intermittent Photic Stimulation (IPS): A technique used during EEG testing where flashing lights are used to provoke certain types of epileptic responses.
  • Responder Rate: The proportion of participants in a clinical trial who experience a significant reduction (usually 50% or more) in seizure frequency.

References

  1. http://clinicaltrials.eu/trial/study-on-prax-628-for-epilepsy-patients-with-light-induced-eeg-response/
  2. http://clinicaltrials.eu/trial/study-on-prax-628-for-adults-with-focal-epilepsy-taking-1-to-3-anti-seizure-medications/